利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

140 条记录 (耗时 0.066 秒)

    Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
    54.
    发明授权
    Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith 有权
    通过测定与其相关的多种抗原来确定乳腺癌和黑素瘤的方法

    公开(公告)号：US06338947B1

    公开(公告)日：2002-01-15

    申请号：US09578378

    申请日：2000-05-25

    申请人： Ugur Sahin ,  Özlem Türeci ,  Yao-Tseng Chen ,  Lloyd J. Old ,  Michael Pfreundschuh

    发明人： Ugur Sahin ,  Özlem Türeci ,  Yao-Tseng Chen ,  Lloyd J. Old ,  Michael Pfreundschuh

    IPC分类号： G01N3353

    CPC分类号： G01N33/57415 ,  C07K14/4748 ,  C12Q1/6886 ,  C12Q2600/106

    摘要： The invention relates to assays for determining breast cancer or melanoma. It has been found that the accuracy of such assays can be improved by assaying samples for three or more known tumor rejection antigen precursors. For breast cancer, the tumor rejection antigen precursors known as SCP-1, NY-ESO-1, and SSX-2 are assayed. For melanoma, SSX-2, NY-ESO-1, and MAGE-3 are assayed. Additional known tumor rejection antigen precursors can also be determined to confirm the assays. It is preferred to carry these out via polymerase chain reactions.

    摘要翻译： 本发明涉及用于确定乳腺癌或黑素瘤的测定法。 已经发现，通过测定三种或更多种已知的肿瘤排斥抗原前体的样品，可以提高这些测定的准确性。 对于乳腺癌，测定称为SCP-1，NY-ESO-1和SSX-2的肿瘤排斥抗原前体。 对于黑素瘤，测定SSX-2，NY-ESO-1和MAGE-3。 还可以确定另外已知的肿瘤排斥抗原前体以确认测定。 优选通过聚合酶链反应进行这些操作。

    Recombinant human anti-FB5 antibodies
    59.
    发明授权
    Recombinant human anti-FB5 antibodies 失效
    重组人抗FB5抗体

    公开(公告)号：US6090930A

    公开(公告)日：2000-07-18

    申请号：US013872

    申请日：1998-01-27

    申请人： Thomas Paul Wallace ,  Francis Carr ,  Wolfgang J. Rettig ,  Pilar Garin-Chesa ,  Lloyd J. Old

    发明人： Thomas Paul Wallace ,  Francis Carr ,  Wolfgang J. Rettig ,  Pilar Garin-Chesa ,  Lloyd J. Old

    IPC分类号： C07K16/30 ,  C12N15/13 ,  C07H21/04 ,  C12N1/20

    CPC分类号： C07K16/30 ,  C07K2317/24 ,  C07K2319/00

    摘要： The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumors. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.

    摘要翻译： 本发明提供了针对抗原FB5特异的几种人源化鼠抗体的产生，其被鼠抗体FB5识别。 FB5抗原在广泛恶性肿瘤的血管内皮细胞的腔表面上表达。 本发明还提供编码人源化FB5特异性抗体的许多多核苷酸，用于产生人源化FB5特异性抗体的表达载体和用于重组产生人源化抗体的宿主细胞。 本发明还提供使用人源化FB5特异性抗体检测癌细胞（体外和体内）的方法。 另外，本发明提供了使用FB5特异性抗体治疗癌症的方法。

    Method for determining oncogenic activity of a substance
    60.
    发明授权
    Method for determining oncogenic activity of a substance 失效
    确定物质致癌活性的方法

    公开(公告)号：US06063359A

    公开(公告)日：2000-05-16

    申请号：US938295

    申请日：1997-09-26

    申请人： Robert Schreiber ,  Lloyd J. Old

    发明人： Robert Schreiber ,  Lloyd J. Old

    IPC分类号： A61K49/00 ,  C12N5/00

    CPC分类号： A61K49/0008

    摘要： A method for screening substances for oncogenic activity is disclosed. The method involves administering the substance to an animal lacking responsiveness to interferon.gamma. and detecting a higher frequency or earlier time of tumor formation in the test animal compared to control animals. In addition, a method is provided for predicting the aggressiveness of a tumor in a patient.

    摘要翻译： 公开了用于筛选致癌活性物质的方法。 该方法包括将物质施用于与对照动物相比，对干扰素γ不敏感的动物和检测动物中较高频率或更早的肿瘤形成时间。 此外，提供了一种用于预测患者肿瘤侵袭性的方法。